350
Participants
Start Date
May 1, 2023
Primary Completion Date
July 30, 2025
Study Completion Date
December 31, 2026
YK-209A tablet
YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
Pemetrexed+carboplatin/Cisplatin
Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
Peking Union Medical College Hospital, Beijing
Beijing Chest Hospital, Capital Medical University, Beijing
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
Peking University Cancer Hospital, Beijing
he First Affiliated Hospital of China Medical University, Shenyang
Jilin Provincial Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Pulmonary Hospital, Shanghai
Jiangsu Province Hospital, Nanjing
The Second Affiliated Hospital of Soochow Universit, Suzhou
Anhui Provincial Chest Hospital, Hefei
Anhui Provincial Hospital, Hefei
The First Affiliated Hospital of Bengbu Medical Colleg, Bengbu
Yijishan Hospital of Wannan Medical College, Wuhu
Cancer Hospital Affiliated to Shandong First Medical University, Jinan
Qilu Hospital of Shandong University, Jinan
The Affiliated Hospital of Qingdao University, Qingdao
Affiliated Hospital of Jining Medical University, Jining
Tianjin Cancer Hospital, Tianjin
Cancer in Zhejiang Province, Hangzhou
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Taizhou First People's Hospital, Taizhou
Taizhou Hospital of Zhejiang Province, Taizhou
The First Affiliated Hospital of Nanchang University, Nanchang
The Second Affiliated Hospital of Nanchang University, Nanchang
Fujian Provincial Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Hunan Cancer Hospital, Changsha
Third Xiangya Hospital, Central South University, Changsha
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhenzhou
he First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou
People's Hospital of Zhongshan City, Zhongshan
Guizhou Provincial People's Hospital, Guiyang
Sichuan Provincial People's Hospital, Chengdu
West China Hospital, Sichuan University, Chengdu
Yunnan Cancer Hospital, Kunming
the First Affiliated Hospital; Medical College of Xi'an Jiaotong University, Xian
The Second Affiliated Hospital of PLA Air Force Medical University, Xian
Gansu Provincial Cancer Hospital, Lanzhou
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Affiliated Hospital of Inner Mongolia Medical University, Hohhot
Jiangxi Cancer Hospital, Nanchang
Shanxi Cancer Hospital, Taiyuan
Suzhou Puhe Pharmaceutical Technology Co., LTD
INDUSTRY